Related Experiment Videos
Screening and clinical implications for BRCA1 and BRCA2 mutation carriers.
1Department of Pediatrics, Texas Children's Cancer Center, Baylor College of Medicine, Houston, USA. splon@bcm.tmc.edu
Journal of Mammary Gland Biology and Neoplasia
|May 20, 2000
Summary
This review covers the history and current status of genetic testing for BRCA1 and BRCA2 mutations. It examines cancer risks, prognosis, and surveillance recommendations for mutation carriers.
Area of Science:
- Genetics
- Oncology
- Medical Diagnostics
Background:
- Genetic mutations in BRCA1 and BRCA2 significantly increase breast cancer risk.
- Understanding these mutations is crucial for risk assessment and personalized medicine.
Purpose of the Study:
- To review the historical development of genetic testing for breast cancer susceptibility genes.
- To discuss the current landscape of BRCA1 and BRCA2 mutation testing in various clinical scenarios.
- To outline risks, prognosis, and surveillance strategies for mutation carriers.
Main Methods:
- Literature review of historical testing methodologies.
- Analysis of current clinical guidelines for genetic testing.
- Synthesis of data on cancer risks and outcomes in mutation carriers.
Main Results:
- Genetic testing for BRCA1 and BRCA2 mutations has evolved significantly.
- Testing is now widely available for at-risk individuals and cancer patients.
- Mutation carriers face elevated risks for breast and other cancers, impacting prognosis.
Conclusions:
- Current recommendations exist for surveillance in mutation carriers.
- Further research is needed to identify factors modifying cancer risk in these individuals.